How is NGS altering our understanding of the importance of combining, aggregating, and analyzing a full range of genomic data to guide therapeutic decisions, especially in rare tumor types?

How is NGS altering our understanding of the importance of combining, aggregating, and analyzing a full range of genomic data to guide therapeutic decisions, especially in rare tumor types?

How is NGS altering our understanding of the importance of combining, aggregating, and analyzing a full range of genomic data — from single mutations and alterations to fusion genes, copy number and RNA expression data — to guide therapeutic decisions, especially in rare tumor types?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Rodrigo Dienstmann, MD

Rodrigo Dienstmann, MD

Principal Investigator, Oncology Data Science (ODysSey) Group
Vall d'Hebron Institute of Oncology
Barcelona, Spain
Computational Oncology Group
Sage Bionetworks
Seattle, Washington, USA